drugset / Trial / NCT00666965
A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to investigate efficacy and safety of SPM 962 in Japanese RLS patients in a multi-center, placebo-controlled double-blind parrallel group comparative study following once-daily multiple transdermal doses of SPM 962 within a range of 2.25 to 6.75 mg/day. Recommended maintainance dose range is also to be investigated.
Timeline
- Start
- 2008-06
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rotigotine | Unknown | 2.25 mg | Other |
| Subject | Rotigotine | Unknown | 4.5 mg | Other |
| Subject | Rotigotine | Unknown | 6.75 mg | Other |